Healthcare / Diagnostics & ResearchHKSE
$2.98
-0.02 (-0.67%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 16%
FCF escenarios
weak_data · normalized FCF $-23.1M · quality 37.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
13/100
F
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$431M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-42.6%
↓Gross Margin
38.5%
↓Debt/Equity
1.36
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-20.9%
FCF CAGR
—
FCF margin
-17.7%
FCF / Net income
0.64x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $184.3M · net income $-51.1M · FCF $-32.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $184.3M | $184.3M | $263.1M | $289.1M | $373.1M |
| Net Income | $-51.1M | $-51.1M | $-42.5M | $-11.6M | $8.1M |
| EBITDA | $-41.9M | $-41.9M | $-32.6M | $9.1M | $49.7M |
| EPS | — | — | -0.29 | -0.08 | 0.06 |
| Gross Margin | 38.5% | 38.5% | 41.2% | 44.1% | 39.2% |
| Operating Margin | -29.2% | -29.2% | -13.0% | -6.2% | 6.1% |
| Net Margin | -27.8% | -27.8% | -16.2% | -4.0% | 2.2% |
| Balance Sheet | |||||
| Debt/Equity | 1.36 | 1.36 | 0.92 | 0.72 | 0.74 |
| Current Ratio | 0.82 | 0.82 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-32.6M | $-32.6M | $8.5M | $-23.1M | $28.1M |
| Returns | |||||
| ROE | -42.6% | -42.6% | -25.3% | -5.5% | 3.9% |
| Valuation | |||||
| P/E | — | — | — | — | 22.50 |
| EV/EBITDA | — | — | — | 23.56 | 5.17 |
| P/B | 3.59 | 3.59 | 0.66 | 0.61 | 0.89 |
| Growth & Yield | |||||
| Revenue Growth | -29.9% | -29.9% | -9.0% | -22.5% | — |
| EPS Growth | — | — | -267.5% | -242.9% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+484.3%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.29 → n/d
Residual
+484.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.